OBJECTIVE：To observe the clinical efficacy and safety of Enalapril folic acid tablet combined with Shenkang injection in the treatment of hypertensive nephropathy. METHODS：90 patients with hypertensive nephropathy were randomly divided into control group and observation group. All patients were given anti-infection， regulating electrolyte balance， supplying amino acids and other conventional treatment. Based on it， control group was orally given Maleic acid enalaprilat folic acid tablet 1 tablet in the morning， once a day； observation group was additionally given 100 ml Shenkang injection adding into 300 ml 10％ Glucose injection by intravenous infusion， 20-30 drops/min， once a day. The treatment course for both groups was 4 weeks. The clinical efficacy， and clearance rate of creatinine（Ccr）， serum creatinine （Scr）， morning urine test urine protein （Up）/urine creatinine （Ucr）， serum malondialdehyde （MDA）， superoxide dismutase （SOD）， total antioxidant capacity （T-AOC） before and after treatment and incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， the difference was statistically significant（P＜0.05）. After treatment， the Ccr， SOD and T-AOC in 2 groups were significantly higher than before， and observation group was higher than control group， Scr and MDA were significantly lower than before， and observation group was lower than control group， the differences were statistically significant（P＜0.05）. Morning urine test Up/Ucr， systolic blood pressure and diastolic blood pressure were significantly lower than before， and the differences were statistically significant（P＜0.05）， however， there was no significant difference between 2 groups（P＞0.05）. And there was no significant difference in the incidence of adverse reactions（P＞0.05）. CONCLUSIONS： Based on the conventional treatment， Enalapril folic acid tablet combined with Shenkang injection has better efficacy than only Enalapril folic acid tablet in the treatment of hypertensive nephropathy，with similar safety.